Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Accumulated Depreciation (2016 - 2023)

Editas Medicine (EDIT) has disclosed Accumulated Depreciation for 9 consecutive years, with $23.5 million as the latest value for Q2 2023.

  • Quarterly Accumulated Depreciation rose 26.38% to $23.5 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $23.5 million through Jun 2023, up 26.38% year-over-year, with the annual reading at $21.5 million for FY2022, 38.81% up from the prior year.
  • Accumulated Depreciation for Q2 2023 was $23.5 million at Editas Medicine, up from $22.0 million in the prior quarter.
  • The five-year high for Accumulated Depreciation was $23.5 million in Q2 2023, with the low at $5.7 million in Q2 2019.
  • Average Accumulated Depreciation over 5 years is $14.2 million, with a median of $13.6 million recorded in 2021.
  • The sharpest move saw Accumulated Depreciation rose 1.0% in 2019, then soared 54.01% in 2020.
  • Over 5 years, Accumulated Depreciation stood at $7.2 million in 2019, then skyrocketed by 54.01% to $11.1 million in 2020, then skyrocketed by 39.77% to $15.5 million in 2021, then surged by 38.81% to $21.5 million in 2022, then grew by 9.13% to $23.5 million in 2023.
  • According to Business Quant data, Accumulated Depreciation over the past three periods came in at $23.5 million, $22.0 million, and $21.5 million for Q2 2023, Q1 2023, and Q4 2022 respectively.